{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:49:37Z","timestamp":1790225377277,"version":"4.1.0"},"reference-count":30,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2019,4,3]]},"DOI":"10.1080\/21645515.2018.1554971","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T22:43:03Z","timestamp":1550702583000},"page":"786-799","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration"],"prefix":"10.1080","volume":"15","author":[{"name":"The MMR-158 Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"04","key":"e_1_3_6_2_1","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean HQ","year":"2013","unstructured":"McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR\u201304):1\u201334.","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"e_1_3_6_3_1","first-page":"49","article-title":"Mumps vaccines: WHO position paper","volume":"82","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. Mumps vaccines: WHO position paper. Wkly Epidemiol Rec. 2007;82(7):49\u201360.","journal-title":"Wkly Epidemiol Rec"},{"issue":"29","key":"e_1_3_6_4_1","first-page":"301","article-title":"Rubella vaccines: WHO position paper","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301\u2013316.","journal-title":"Wkly Epidemiol Rec"},{"issue":"17","key":"e_1_3_6_5_1","first-page":"205","article-title":"Measles vaccines: WHO position paper","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(17):205\u2013228.","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"e_1_3_6_6_1","first-page":"120","article-title":"Measles\u2013United States, 2000","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","unstructured":"Centers for Disease Control and Prevention. Measles\u2013United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(6):120\u2013123.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_6_7_1","first-page":"325","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. Chapter 20: Rubella. In: Epidemiology and prevention of vaccine-preventable diseases. 13th ed. \u201cThe Pink Book\u201d: Centers for Disease Control and Prevention, Washington DC; 2012. p. 325\u2013340.","edition":"13"},{"key":"e_1_3_6_8_1","unstructured":"Centers for Disease Control and Prevention. Mumps cases and outbreaks. Centers for disease control and prevention; 2018 Mar 6 [accessed 2018 Mar 13]. https:\/\/www.cdc.gov\/mumps\/outbreaks.html."},{"key":"e_1_3_6_9_1","unstructured":"Centers for Disease Control and Prevention. Measles cases and outbreaks. Centers for disease control and prevention; 2017 Oct 13 [accessed 2017 Oct 13]. https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html."},{"key":"e_1_3_6_10_1","unstructured":"European Medicines Agency. Priorix. Annex III: Summary of product characteristics labelling and package leaflet; 2012 [accessed 2018 Jan 15]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Priorix_30\/WC500124199.pdf."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363190-00012"},{"key":"e_1_3_6_12_1","unstructured":"European Medicines Agency. Guideline on clinical evaluation of new vaccines. EMEA\/CHMP\/VWP\/164653\/2005; 2006. http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003870pdf."},{"key":"e_1_3_6_13_1","unstructured":"World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO\/DRAFT; 2016 Jan 27 http:\/\/wwwwhoint\/biologicals\/Clinical_guidelines_27_January_2016pdf."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.10.065"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.017"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.064"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2010.03244.x"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.04.001"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074-0276130351"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.1009"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.26.18914-en"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/520028"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1502527"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-29"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00131-10"},{"key":"e_1_3_6_26_1","article-title":"Correlates of vaccine-induced protection: methods and implications","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Correlates of vaccine-induced protection: methods and implications. Immunization Vaccines Biol. WHO\/IVB\/1301; 2013. http:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/84288\/WHO_IVB_1301_engpdf;jsessionid=18887B1B09124C870BF9B348E23F93A1?sequence=1.","journal-title":"Immunization Vaccines Biol"},{"key":"e_1_3_6_27_1","unstructured":"Food and Drug Administration. Kinrix. Package insert; 2018 Feb 12. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM241453.pdf."},{"key":"e_1_3_6_28_1","unstructured":"Food and Drug Administration. Varixax. Package insert; 2018 Feb 12. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142813.pdf."},{"key":"e_1_3_6_29_1","unstructured":"World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO\/EPI\/GEN\/939; 1993. http:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/70486\/WHO_EPI_GEN_939_engpdf?sequence=1&isAllowed=y."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318259fc8a"},{"key":"e_1_3_6_31_1","unstructured":"World Health Organization. WHO international standard pertussis antiserum (Human) 1st IS NIBSC code: 06\/140; 2013. http:\/\/www.nibsc.org\/documents\/ifu\/06-140.pdf."}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2018.1554971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:43:02Z","timestamp":1707896582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2018.1554971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1080\/21645515.2018.1554971"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2018.1554971","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}